Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Helmerich & Payne Inc. Common Stock (HP) vs BIO-TECHNE Corp (TECH) Price & Performance

Helmerich & Payne Inc. Common StockTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Helmerich & Payne Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.86B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.9× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays the higher dividend (2.59%). Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and BIO-TECHNE Corp for 64 Days on average.

HPTECH
Market Cap
$3.86B$11.37B
Volume
870,3711,544,768
Sector
EnergyHealth
52-Week High
$47.64$72.61
52-Week Low
$23.11$43.31
Typical Hold Time
0 Days64 Days
Enterprise Value
$5.49B$11.40B
Dividend Yield
2.59%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Helmerich & Payne Inc. Common Stock

No Aura AI signal available yet.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.48, down 0.11% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average support. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. The company's pending acquisition by Merck KGaA for $73.00 per share, approved by shareholders (PRNewsWire, 2026-09-23), is a key near-term catalyst. Fundamentals indicate solid profitability with a 65.77% gross margin but elevated valuation ratios like a P/E of 62.52.

The outlook is dominated by the acquisition, offering a clear exit near the current price. Upside is capped by the deal price, while execution risks or regulatory hurdles pose downside. Analyst sentiment is neutral with a consensus hold rating. The stock presents a low-risk opportunity for merger arbitrage but limited growth potential for long-term investors absent competitive threats or integration challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HP
100% Buy0% Sell
Avg holding period · 0 Days
TECH
100% Buy0% Sell
Avg holding period · 64 Days

About Helmerich & Payne Inc. Common Stock

Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.

Read more on HP →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →